

CTSA Program KL2 Scholar in the News:

Understanding and treating cardiovascular effects of cancer treatments in women with breast cancer

- **BRCA1/2 mutation carriers** with history of breast cancer treated with anthracyclines have no significant differences in cardiac function compared to women with history of sporadic breast cancer
- In a **prospective multicenter pilot study** we **demonstrated cardiac safety of HER2 targeted therapy** in patients with **HER2-positive breast cancer** and **reduced left ventricular function**



“Multidisciplinary collaboration between cardiology and oncology offers an opportunity to advance care and improve outcomes of women with breast cancer”

Ana Barac, MD, PhD

